Literature DB >> 35366088

Rectal MRI radiomics inter- and intra-reader reliability: should we worry about that?

Henry C Kwok1, Charlotte Charbel1, Jayasree Chakraborty2, Natally Horvat3, Sofia Danilova1, Joao Miranda4, Natalie Gangai1, Iva Petkovska1.   

Abstract

PURPOSE: The aim of this review paper is to summarize the current literature regarding inter- and intra-reader reliability of radiomics on rectal MRI.
METHODS: Original studies examining treatment response prediction in patients with rectal cancer following neoadjuvant therapy using rectal MRI-based radiomics between January 2010 and December 2021 were identified via a PubMed/Medline search. Studies in which intra- and/or inter-reader reliability had been reported were included in this review.
RESULTS: Thirteen studies were selected, with an average number of patients of 145 (range, 20-649). All included studies evaluated T2-weighted imaging (T2WI) and/or diffusion-weighted imaging (DWI) sequences, while 3/13 (23%) also evaluated the contrast-enhanced T1-weighted imaging (T1WI) sequence. Most of the selected studies involved two readers (10/13, 77%), 6/13 (46%) studies used baseline MRI only, 1/13 (8%) study used restaging MRI only, and 6/13 (46%) used both. Segmentation was performed manually in 10/13 (77%) studies, and in a slight majority of studies (7/13, 54%), the entire tumor volume (3D VOI) was segmented, while 4/13 (31%) studies segmented the 2D ROI and 2/13 (15%) segmented both. Intraclass correlation coefficient (ICC) on intra-reader agreement varied from 0.73 to 0.93. ICC to assess inter-reader varied from 0.60 to 0.99. Overall, features obtained from baseline rectal MRI, using 3D VOI and first-order features, had higher agreement.
CONCLUSION: Based on our qualitative assessment of a small number of non-dedicated studies, there seems to be good reliability, particularly among low-order features extracted from the entire tumor volume using baseline MRI; however, direct evidence remains scarce. More targeted research in this area is required to quantitatively verify reliability, and before these novel radiomic techniques can be clinically adopted.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Agreement; Machine learning; Magnetic resonance imaging; Rectal cancer; Reliability

Mesh:

Year:  2022        PMID: 35366088      PMCID: PMC9189624          DOI: 10.1007/s00261-022-03503-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  25 in total

1.  Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.

Authors:  Monique Maas; Regina G H Beets-Tan; Doenja M J Lambregts; Guido Lammering; Patty J Nelemans; Sanne M E Engelen; Ronald M van Dam; Rob L H Jansen; Meindert Sosef; Jeroen W A Leijtens; Karel W E Hulsewé; Jeroen Buijsen; Geerard L Beets
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.

Authors:  Kazushige Kawai; Soichiro Ishihara; Hiroaki Nozawa; Keisuke Hata; Tomomichi Kiyomatsu; Teppei Morikawa; Masashi Fukayama; Toshiaki Watanabe
Journal:  Dis Colon Rectum       Date:  2017-04       Impact factor: 4.585

3.  Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point.

Authors:  Jose G Guillem; David B Chessin; Jinru Shia; Harvey G Moore; Madhu Mazumdar; Bianca Bernard; Philip B Paty; Leonard Saltz; Bruce D Minsky; Martin R Weiser; Larissa K F Temple; Alfred M Cohen; W Douglas Wong
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

Review 4.  A primer on texture analysis in abdominal radiology.

Authors:  Natally Horvat; Joao Miranda; Maria El Homsi; Jacob J Peoples; Niamh M Long; Amber L Simpson; Richard K G Do
Journal:  Abdom Radiol (NY)       Date:  2021-11-26

5.  Accuracy of MRI for predicting the circumferential resection margin, mesorectal fascia invasion, and tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Authors:  Seung Ho Kim; Jeong Min Lee; Hee Sun Park; Hyo Won Eun; Joon Koo Han; Byung Ihn Choi
Journal:  J Magn Reson Imaging       Date:  2009-05       Impact factor: 4.813

Review 6.  CT Texture Analysis: Definitions, Applications, Biologic Correlates, and Challenges.

Authors:  Meghan G Lubner; Andrew D Smith; Kumar Sandrasegaran; Dushyant V Sahani; Perry J Pickhardt
Journal:  Radiographics       Date:  2017 Sep-Oct       Impact factor: 5.333

7.  Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.

Authors:  Andrew G Renehan; Lee Malcomson; Richard Emsley; Simon Gollins; Andrew Maw; Arthur Sun Myint; Paul S Rooney; Shabbir Susnerwala; Anthony Blower; Mark P Saunders; Malcolm S Wilson; Nigel Scott; Sarah T O'Dwyer
Journal:  Lancet Oncol       Date:  2015-12-17       Impact factor: 41.316

Review 8.  Radiomics: the facts and the challenges of image analysis.

Authors:  Stefania Rizzo; Francesca Botta; Sara Raimondi; Daniela Origgi; Cristiana Fanciullo; Alessio Giuseppe Morganti; Massimo Bellomi
Journal:  Eur Radiol Exp       Date:  2018-11-14

9.  Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis.

Authors:  Anup Kasi; Saqib Abbasi; Shivani Handa; Raed Al-Rajabi; Anwaar Saeed; Joaquina Baranda; Weijing Sun
Journal:  JAMA Netw Open       Date:  2020-12-01

10.  A field strength independent MR radiomics model to predict pathological complete response in locally advanced rectal cancer.

Authors:  Davide Cusumano; Gert Meijer; Jacopo Lenkowicz; Giuditta Chiloiro; Luca Boldrini; Carlotta Masciocchi; Nicola Dinapoli; Roberto Gatta; Calogero Casà; Andrea Damiani; Brunella Barbaro; Maria Antonietta Gambacorta; Luigi Azario; Marco De Spirito; Martijn Intven; Vincenzo Valentini
Journal:  Radiol Med       Date:  2020-08-24       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.